Naslov
Inflammatory bowel diseases and hematological tumours

Autori
Babić, Žarko ; Rob, Zrinka ; Andabak, Maja ; Medić, Barbara ; Banić, Marko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Acta clinica Croatica. Supplement, 60 (2021), 2 / Ljubičić, Neven ; Virović Jukić, Lucija - Zagreb : Hrvatsko gastroenterološko društvo, 2021, 75-75

Skup
9. kongres Hrvatskog gastroenterološkog društva = 9th congress of the Croatian society of gastroenterology

Mjesto i datum
Zagreb, Hrvatska, 28.10.2021. - 30.10.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
IBD ; hematologic tumors

Sažetak
Introduction and Aim: Gastrointestinal and extraintestinal malignancies are long-term complications in patients with inflammatory bowel disease (IBD), likely as a result of chronic inflammation and the use of immunomodulatory medications used to control inflammation (1, 2). Here, we assessed the occurrence of malignancies in two patients that were treated with azathioprine, in a large tertiary IBD center at the University Hospital Dubrava, Zagreb. In a patients with IBD there is a higher risk of intestinal and extraintestinal malignancies due to therapy with thiopurines due to general population (3). Immunomodulatory therapy that was used to treat inflammation in IBD patients, as AZA-6, 6-MP are also increasing risks of different types of extra intestinal malignancies likewise Non-Hodgkin lymphoma (NHL), non-melanotic skin cancer or melanoma and urothelial carcinoma (1-3). Since there is no enough data from previous literature and those conclusions where quite contradictory we decided to present two patients with IBD and extra intestinal malignancies due to immunomodulatory therapy. Methods Both patients where diagnosed with IBD/UC and treated with AZA-6. While treated with immunomodulatory therapy and continuous monitoring due to basic clinical course, both of them developed hematological malignancies. Male patient (27 yrs. old, 10 years with IBD, total duration of intermittent therapy with AZA-6 of 3 years) of during his therapeutic procedures and therapy developed acute monocyte leukemia and the other female patient (79 yrs. old, 40 years with IBD, total duration of intermittent therapy with AZA-6 of 5 years) developed plasmacytoma/multiple myeloma, diagnosed to the standard procedure. Conclusion: Our data supports the assumption of other authors, that a long-standing disease course and immunosuppressive therapy increase the risk for developing malignancies in IBD patients. Wide use of immunomodulatory therapy in treating IBD patients raises actually big concerns because of potential risks of developing malignancies. Since the data from different sources were quite contradictory, we suggest more clinical monitoring. Reference: 1. Medanchi M, Zeits J, Barthel C, Samaras P, Scharl S, Sulz MC. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience Digestion. 2016 ; 94(1):1-8. doi: 10.1159/000447259. Epub 2016 Jun 18. PMID: 27318857 ; DOI: 10.1159/000447259 2. Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis 2015 Mar ; 21(3):674-98. doi: 10.1097/MIB.0000000000000243. PMID: 25545375 ; DOI: 10.1097/MIB.0000000000000243 3. Kotlyar DS, Lewis JD, Beaugerie L , Tierney A , Brensinger CB, Gisbert JP. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6- mercaptopurine: a meta- analysis, Clin Gastroenterol Hepatol 2015 May ; 13(5):847-58.e4 ; quiz e48-50. ; doi: 10.1016/j.cgh.2014.05.015. Epub 2014 May 28. e- mail: zarko.babic@zg.t-com.hr

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA